Inhibiting breast cancer by targeting the thromboxane A2 pathway
Breast cancer: Pathway target identified The identification of a signaling pathway connected to the progression of breast cancer could prove a valuable therapeutic target. The breast cancer treatment tamoxifen, although successful, is limited to certain tumor types, and so the search is on to pinpoi...
Guardado en:
Autores principales: | Haitao Li, Mee-Hyun Lee, Kangdong Liu, Ting Wang, Mengqiu Song, Yaping Han, Ke Yao, Hua Xie, Feng Zhu, Michael Grossmann, Margot P. Cleary, Wei Chen, Ann M. Bode, Zigang Dong |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/07d9df38e8884ed990883481bc3a6b23 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeting ornithine decarboxylase (ODC) inhibits esophageal squamous cell carcinoma progression
por: Wei He, et al.
Publicado: (2017) -
The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review
por: Małgorzata Szczuko, et al.
Publicado: (2021) -
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia
por: Sara Alberti, et al.
Publicado: (2020) -
Precision oncology- the future of personalized cancer medicine?
por: Ann M. Bode, et al.
Publicado: (2017) -
Precision medicine: the foundation of future cancer therapeutics
por: Seung Ho Shin, et al.
Publicado: (2017)